Advertisement

Topics

The Medicines Company and Alnylam Pharmaceuticals, Inc. Company Profile

12:01 EDT 24th March 2019 | BioPortfolio

The Medicines Company is a biopharmaceutical company driven by an overriding purpose – to save lives, alleviate suffering and contribute to the economics of healthcare. The Company’s mission is to create transformational solutions to address the most pressing healthcare needs facing patients, physicians and providers in three critical therapeutic areas: serious infectious disease care, cardiovascular care and surgery and perioperative care. The Company is headquartered in Parsippany, New Jersey, with global innovation centers in California and Switzerland.


News Articles [1475 Associated News Articles listed on BioPortfolio]

Deals and M&As this week: Alnylam Pharmaceuticals, Novartis

Alnylam Pharmaceuticals has entered an agreement with Medison Pharma to commercialise its RNAi therapeutic Onpattro in Israel. Onpattro is indicated...Read More... The post Deals and M&As this we...

Alnylam to Webcast Presentation at Cowen & Company 39th Annual Health Care Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Cowen & Comp...

Alnylam Announces Submission Of NDA In Japan For ONPATTRO

WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals, Inc. (ALNY) announced it has submitted a New Drug Application (NDA) to Japan's Pharmaceuticals and Medical Devices Agency for approval of patisiran ...

Alnylam to Webcast R&D Day

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming R&D Day, including a live video s...

Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug

A few weeks ago, Alnylam Pharmaceuticals indicated it might seek a speedy FDA approval for what could be the second-ever RNA interference medicine to market. After meeting with regulators, however, th...

With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug

Alnylam Pharmaceuticals was just cleared to market the first-ever RNA interference medicine. The second one may not be that far behind. Alnylam (NASDAQ: ALNY), of Cambridge, MA, said this morning that...

Alnylam to Webcast Presentation at the 2018 Cantor Global Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 2018 Cantor Glob...

Alnylam reports further progress on broadening the therapeutic potential of RNAi

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today further progress on the Company's platform efforts in extrahepatic delivery of novel siRNA conjugates, including c...

PubMed Articles [380 Associated PubMed Articles listed on BioPortfolio]

Alnylam launches era of RNAi drugs.

Swimming activity in zebrafish larvae exposed to veterinary antiparasitic pharmaceuticals.

Veterinary antiparasitic pharmaceuticals have been detected in surface waters and several of these pharmaceuticals act on the nervous system on the target organisms implying that neurological effects ...

Lost medicines: a longer view of the pharmaceutical industry with the potential to reinvigorate discovery.

It is widely understood that the 1962 Kefauver-Harris Amendment to the Food, Drug and Cosmetics Act ushered in the modern regulation of medicines requiring a combination of safety and efficacy. Howeve...

Insight into the distribution of pharmaceuticals in soil-water-plant systems.

Pharmaceuticals in agricultural soils originating from irrigation with treated wastewater and land-applied biosolids can enter field crops. However, little is known about the role of pore water in pla...

Review: The Health Consequences of Falsified Medicines.

To analyse and present the literature describing the health consequences of falsified medicines, focusing on mortality and morbidity, as well as the scale of the issue, the geographic extent, the medi...

Clinical Trials [782 Associated Clinical Trials listed on BioPortfolio]

Epidemiology of Cardiovascular and Non-Cardiovascular Risk In Chicago

To continue the comprehensive research program on the epidemiology of cardiovascular and other major chronic diseases, including cancer and diabetes, in four Chicago population cohorts. T...

Buspirone Hydrochloride 30mg Tablets, Fasting

This study will compare the relative bioavailability (rate and extent of absorption) of 30 mg Buspirone Hydrochloride Tablets by TEVA Pharmaceuticals Industries, Ltd. with that of 30 mg BU...

To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 1 mg

To demonstrate the relative bioavailability of Alprazolam tablets, 1 mg.

Immunogenicity and Safety of Kinrix + MMR With and Without Varicella Vaccine in Healthy Children 4-6 Years

The purpose of the study is to evaluate the immunogenicity and safety of Kinrix when co-administered with varicella (Varivax® [varicella virus vaccine live], Merck and Company) and MMR va...

Minocycline HCl Extended Release Tablets 135 mg Oral Bioequivalence Study

To determine single-dose oral bioequivalence of Minocycline HCl Extended Release Tablets 135 mg manufactured by Amneal Pharmaceuticals Co.(I)Pvt. Ltd., India and SOLODYN® (minocycline h...

Companies [3328 Associated Companies listed on BioPortfolio]

Alnylam Pharmaceuticals, Inc. and The Medicines Company

The Medicines Company and Alnylam Pharmaceuticals, Inc.

The Medicines Company is a biopharmaceutical company driven by an overriding purpose – to save lives, alleviate suffering and contribute to the economics of healthcare. The C...

Alnylam Europe AG

Alnylam ist ein biopharmazeutisches Unternehmen, das neuartige Therapeutika auf Basis der RNA-Interferenz (RNAi) entwickelt und hierbei eine führende Position inne hat. Die RNAi stellt einen Durchbru...

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, a leader in RNAi therapeutics, is a biopharmaceutical company developing novel therapeutics based on a breakthrough in biology known as RNA interference, or RNAi; a discovery ...

Ligand Pharmaceuticals Incorporated and The Medicines Company

The Medicines Company (NASDAQ: MDCO) provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise m...

More Information about "The Medicines Company and Alnylam Pharmaceuticals, Inc." on BioPortfolio

We have published hundreds of The Medicines Company and Alnylam Pharmaceuticals, Inc. news stories on BioPortfolio along with dozens of The Medicines Company and Alnylam Pharmaceuticals, Inc. Clinical Trials and PubMed Articles about The Medicines Company and Alnylam Pharmaceuticals, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of The Medicines Company and Alnylam Pharmaceuticals, Inc. Companies in our database. You can also find out about relevant The Medicines Company and Alnylam Pharmaceuticals, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...


Corporate Database Quicklinks



Searches Linking to this Company Record